IPO - Omada Health, Inc.

Form Type: 424B4

Filing Date: 2025-06-09

Corporate Action: Ipo

Type: New

Accession Number: 000119312525137394

Filing Summary: Omada Health, Inc. is conducting its initial public offering (IPO) by offering 7,900,000 shares of common stock at an initial price of $19.00 per share. The shares are set to be listed on the Nasdaq Global Select Market under the symbol 'OMDA'. The approval has been granted for listing, and the underwriting details indicate total proceeds to the company amounting to approximately $139.6 million after underwriting discounts. Additionally, underwriters have an option to purchase up to 1,185,000 additional shares at the IPO price within 30 days. The filing cautions that investing involves a high degree of risk and highlights that neither the Securities Exchange Commission nor state securities commissions have approved the securities or passed on the adequacy of the prospectus. The shares are expected to be delivered to purchasers on June 9, 2025. Omada aims to address chronic health issues through a virtual care model, focusing on obesity, diabetes, and related conditions. The document includes information about customer retention, financial conditions, risk factors, and advanced product offerings designed to better support members' health needs. Lastly, it emphasizes the company's growth metrics and milestones achieved since its inception in 2011.

Form Type: 8-K

Filing Date: 2025-06-09

Corporate Action: Ipo

Type: New

Accession Number: 000119312525137809

Filing Summary: On June 9, 2025, Omada Health, Inc. filed its restated certificate of incorporation and its amended and restated bylaws with the Secretary of State of Delaware, effective in connection with the closing of its initial public offering (IPO). The IPO was reported to involve an aggregate of 9,085,000 shares of common stock sold to the public at a price of $19.00 per share, which included the full exercise of an option by underwriters to purchase an additional 1,185,000 shares. The total gross proceeds from the IPO were $172,615,000 before deductions for underwriting discounts and commissions, and estimated offering expenses.

Form Type: 8-A12B

Filing Date: 2025-06-03

Corporate Action: Ipo

Type: New

Accession Number: 000119312525134123

Filing Summary: Omada Health, Inc. is filing Form 8-A12B for the registration of its common stock with a par value of $0.001 per share to be listed on The Nasdaq Stock Market LLC. This registration is pursuant to Section 12(b) of the Securities Exchange Act of 1934, indicating that the company's shares will be publicly available for trading. The Registration Statement related to this filing is identified as 333-287156, which initially was filed with the SEC on May 9, 2025. The company’s principal executive offices are located at 500 Sansome Street, Suite 200, San Francisco, California, 94111. No exhibits are required for this form as no other securities are registered with The Nasdaq Stock Market LLC, and the registration does not pertain to Section 12(g) of the Act.

Form Type: S-1/A

Filing Date: 2025-05-29

Corporate Action: Ipo

Type: New

Accession Number: 000119312525129904

Filing Summary: Omada Health, Inc. is conducting its initial public offering (IPO) and is offering 7,500,000 shares of common stock at an anticipated price between $18.00 and $20.00 per share. This offering marks the first time the company's stock will be publicly available, with no existing public market for the shares. The company plans to list its shares on the Nasdaq Global Market under the symbol 'OMDA'. Omada Health is classified as an 'emerging growth company', allowing it to adhere to reduced reporting requirements. The underwriters have a 30-day option to purchase up to 1,125,000 additional shares at the IPO price. The estimated funds from the offering will help support the company's operational growth and expansion initiatives. Omada aims to redefine the management of chronic conditions, filling gaps in care that traditional healthcare models fail to address, promoting a model termed 'Between-Visit Care', which leverages technology and a team-based approach to offer continuous support to its members.

Form Type: S-1

Filing Date: 2025-05-09

Corporate Action: Ipo

Type: New

Accession Number: 000119312525116907

Filing Summary: Omada Health, Inc. is filing a registration statement to conduct its initial public offering (IPO) of common stock. There is no existing public market for the company's shares, and the anticipated price range for the IPO is not specified. The company plans to list its common stock on the Nasdaq Global Market under the symbol 'OMDA'. As an emerging growth company, Omada has opted for certain reduced public company reporting obligations. The commencement of the public sale is intended as soon as practicable after the registration statement becomes effective. The document outlines Omada's mission to provide comprehensive virtual care between doctor visits, particularly targeting chronic conditions such as obesity and diabetes. The prospectus indicates a high level of interest and potential, with significant metrics reflecting a strong customer base and retention rates. The underwriters for this IPO include Morgan Stanley, Goldman Sachs & Co. LLC, and J.P. Morgan, among others. A focus on the advantages of their unique care model, which integrates health coaching and technology, is presented as a key selling point.

Form Type: DRS/A

Filing Date: 2025-03-14

Corporate Action: Ipo

Type: New

Accession Number: 000095012325003084

Filing Summary: Omada Health, Inc. is initiating its Initial Public Offering (IPO) by filing a draft registration statement with the U.S. Securities and Exchange Commission. The registration statement is part of the process for public offerings under the Securities Act of 1933 and has not yet been publicly filed. This document outlines details regarding the offering of common stock and mentions that the company's initial public offering price is expected to be between certain undefined amounts per share. Omada Health is categorized as an ‘emerging growth company’, which allows it to follow reduced public company reporting requirements. The prospectus includes sections on risk factors, the use of proceeds, and management's financial discussion. The company is applying to list its common stock on the Nasdaq Global Market under the symbol 'OMDA'. The underwriters are expected to deliver the shares to purchasers in 2024, and the company aims to commence the public sale after the effective date of this registration statement.

Form Type: DRS/A

Filing Date: 2025-02-14

Corporate Action: Ipo

Type: New

Accession Number: 000095012325002131

Filing Summary: Omada Health, Inc. is filing its initial public offering (IPO) registration statement under Form DRS/A. The document indicates it has not yet been publicly filed and consists of confidential information submitted to the U.S. Securities and Exchange Commission (SEC). The proposed offering involves shares of common stock, with expectations to list on the Nasdaq under the symbol 'OMDA'. The IPO aims to address the healthcare needs of individuals with chronic conditions and is characterized by a high degree of risk for investors. Notably, Omada Health aims to offer a range of virtual care programs and is deemed an emerging growth company, which allows it to utilize certain reduced public company reporting requirements. The expected commencement date for the offering is soon after the registration statement becomes effective. The prospectus underscores that investing in their stock comes with inherent risks and that no public market currently exists for its shares. There is no definitive pricing outlined, although general parameters for the prospective share price are indicated to be determined prior to the offering.

Form Type: DRS/A

Filing Date: 2024-11-18

Corporate Action: Ipo

Type: New

Accession Number: 000095012324012020

Filing Summary: Omada Health, Inc. is filing a draft registration statement for its initial public offering (IPO) on November 18, 2024. The company, incorporated in Delaware, has applied to list its common stock on the Nasdaq Global Market under the trading symbol 'OMDA'. The preliminary prospectus indicates that no public market currently exists for its shares, with anticipated initial offering prices yet to be determined. The document emphasizes that the registration statement has not yet been publicly filed and remains confidential. Omada is characterized as an 'emerging growth company', which allows it to comply with reduced public reporting requirements. The filing outlines the structure of the offering, including details on underwriting fees and the potential risks associated with investing. The company projects its growth and future market relevance, highlighting significant enrollment statistics and customer metrics as of June 30, 2024, such as 1 million members enrolled and 90% customer retention. The document includes sections on financial data, risk factors, management discussions, and intended use of proceeds, stressing investors should consider risk factors before investing.

Form Type: DRS/A

Filing Date: 2024-08-07

Corporate Action: Ipo

Type: New

Accession Number: 000095012324007329

Filing Summary: Omada Health, Inc. is initiating its initial public offering (IPO) of common stock, submitting a registration statement under the Securities Act of 1933 on August 7, 2024. The offering is intended to provide a public market for its shares for the first time, as no public market currently exists for its common stock. The anticipated price range for the initial public offering per share is not specified, and the company plans to list its shares on the Nasdaq Global Market under the symbol 'OMDA'. The document highlights that Omada is an 'emerging growth company' that has elected to comply with reduced public company reporting requirements. The registration includes general corporate disclosure, preliminary prospectus information, risk factors involved in investing, and potential market and industry data. Furthermore, the company emphasizes its innovative healthcare model focusing on delivering personalized care via technology and a team of healthcare specialists, aimed at improving chronic condition outcomes. The underwriters are granted a 30-day option to purchase additional shares at the initial public offering price, less underwriting discounts. The document also notes that the effective date of the registration will be determined upon further amendments and SEC approvals.

Form Type: DRS

Filing Date: 2024-06-24

Corporate Action: Ipo

Type: New

Accession Number: 000095012324006288

Filing Summary: Omada Health, Inc. is filing a draft registration statement under the Securities Act of 1933 for its initial public offering (IPO) of common stock. The company aims to commence the sale to the public as soon as practicable following the effective date. Omada, based in San Francisco, California, is positioned as an emerging growth company and intends to list its shares on the Nasdaq Global Market under the symbol 'OMDA'. The preliminary prospectus highlights that no public market currently exists for the stock, and it warns potential investors of the inherent risks involved in the investment. It details the company's health care approach, focusing on chronic disease management and prevention, while emphasizing the success it has achieved in serving over one million members and partnering with various employers and health plans. Moreover, the prospectus outlines Omada's mission to deliver engaging and integrated virtual care between doctor visits, exceeding the traditional care model.